Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile (PREVADIFF)
Primary Purpose
Clostridium Difficile Infection
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Patients
Sponsored by
About this trial
This is an interventional other trial for Clostridium Difficile Infection
Eligibility Criteria
Inclusion Criteria:
- Adult patient (≥ 18 years) hospitalized in targeted short-stay (MCO) and long-stay (LTC) services for each of the three identified regions
- French-speaking patient
- Patient affiliated to the social security system or, failing that, to another health insurance system
- Patient able to give free, informed and written consent
Exclusion Criteria:
- History of blood transfusion, vascular filling, dialysis or polyvalent immunoglobulin infusion.
- Patient deprived of liberty
- Patient under court protection
- Patient in an emergency situation
- Patients unable to give personal consent, including adults under guardianship
Sites / Locations
- Groupe Hospitalier Paris Saint-JosephRecruiting
- Hôpital Sainte-Marie Paris
- Centre de SSR Pierre Chevalier
- Hôpital d'Instruction des Armées Sainte Anne,
- Centre Hospitalier de Valenciennes
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patients
Arm Description
On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
Outcomes
Primary Outcome Measures
Overall seroprevalence of antibodies to the major virulence factors of Clostridioides difficile
This outcome corresponds to the percentage of patients with antibodies detected against each of the antigens studied (toxins and Clostridioides difficile colonization factors).
Secondary Outcome Measures
Immune response profiles
This outcome corresponds to the comparison of antibody positivity rates according to different groups such as gender, age groups, geographical location and community or hospital status.
Observed immune responses
This outcome corresponds to the distribution of serum antibody titers to each antigen of interest (IgG and IgM) and rate of patients with neutralizing antibodies (cell culture cytotoxicity test) among patients with detectable antibodies.
Determination of the seroprevalence of antibodies directed specifically against binary toxins
This outcome corresponds to the percentage of patients with antibodies to C. difficile binary toxins.
Full Information
NCT ID
NCT05192148
First Posted
December 30, 2021
Last Updated
April 6, 2023
Sponsor
Fondation Hôpital Saint-Joseph
1. Study Identification
Unique Protocol Identification Number
NCT05192148
Brief Title
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
Acronym
PREVADIFF
Official Title
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2021 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Hôpital Saint-Joseph
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Data on the seroprevalence of antibodies to Clostridioides difficile surface proteins and toxins are scarce.
In 1983, Viscidi et al. showed that antibodies to C. difficile toxins A and B were detected in 60 to 70% of an adult population. Two-thirds of the adults tested had a serological trace, probably linked to a previous encounter with C. difficile.
One of the hypotheses raised would be that exposure to this pathogen occurs very early and regularly throughout our lives. Indeed, in this study, antibodies to C. difficile toxins were detected from early childhood and persisted over time even after 60 years. The antibody response did not appear to vary with age or terrain. However, these results were only qualitative and did not allow for inter-individual variations due to the limitations of the techniques used at the time. Finally, in this work, it was important to underline that the neutralizing character of the cytotoxic effect of toxins on cell culture was not observed in all patients.
Since this seminal work, several studies have shown that the host immune response plays a central role in the pathophysiology of C. difficile infections (CDI). In 2000, Kyne et al. showed that after colonization with a toxigenic C. difficile strain, patients with asymptomatic carriage had significantly higher serum levels of IgG directed against toxin A than patients who developed disease. Subsequently, they also showed in 2001 that a serum response directed against toxin A after a first episode of CDI was associated with less recurrence. Finally, Leav et al. showed in 2010 that a serum response directed against C. difficile toxin B was also associated with protection against recurrent forms.
Several studies have also suggested that the host immune response, this time directed against colonization factors, could also play a major role in the evolution and prognosis of CDI. In a previous study, investigators showed a significant difference in the level of anti-SlpA antibodies (S-layer component) between CDI patients and control patients.
At the same time, the epidemiology of CDI has changed since 2003 due to the emergence of a new epidemic and hypervirulent strain (PCR ribotype 027) producing a third toxin, the binary toxin. The humoral response to this toxin remains poorly described to date.
On the basis of these numerous studies, new therapeutic immunization strategies (active or passive) aimed at neutralizing the action of C. difficile toxins and colonization factors have been or are being developed.
However, it remains to identify the patients likely to benefit from these innovative strategies. This was the main objective of the SERODIFF study (currently being finalized), which identified certain patient profiles in which no seroconversion or isotype class switching of antibodies was observed following CDI. The absence of neutralizing antibody production would seem to correlate with recurrent forms. Thus, these patients would be those who could be eligible for a passive immunization strategy such as the administration of anti-toxin B monoclonal antibodies, bezlotoxumab, recently marketed in France.
In this study, investigators aim to evaluate the seroprevalence stratified by age group, sex and by the main risk factors for CDI. Furthermore, the neutralizing and protective effect of the detected antibodies against C. difficile virulence factors will be studied.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile Infection
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
840 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients
Arm Type
Experimental
Arm Description
On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
Intervention Type
Other
Intervention Name(s)
Patients
Intervention Description
On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
Primary Outcome Measure Information:
Title
Overall seroprevalence of antibodies to the major virulence factors of Clostridioides difficile
Description
This outcome corresponds to the percentage of patients with antibodies detected against each of the antigens studied (toxins and Clostridioides difficile colonization factors).
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Immune response profiles
Description
This outcome corresponds to the comparison of antibody positivity rates according to different groups such as gender, age groups, geographical location and community or hospital status.
Time Frame
Day 1
Title
Observed immune responses
Description
This outcome corresponds to the distribution of serum antibody titers to each antigen of interest (IgG and IgM) and rate of patients with neutralizing antibodies (cell culture cytotoxicity test) among patients with detectable antibodies.
Time Frame
Day 1
Title
Determination of the seroprevalence of antibodies directed specifically against binary toxins
Description
This outcome corresponds to the percentage of patients with antibodies to C. difficile binary toxins.
Time Frame
Day 1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patient (≥ 18 years) hospitalized in targeted short-stay (MCO) and long-stay (LTC) services for each of the three identified regions
French-speaking patient
Patient affiliated to the social security system or, failing that, to another health insurance system
Patient able to give free, informed and written consent
Exclusion Criteria:
History of blood transfusion, vascular filling, dialysis or polyvalent immunoglobulin infusion.
Patient deprived of liberty
Patient under court protection
Patient in an emergency situation
Patients unable to give personal consent, including adults under guardianship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alban LE MONNIER, MD, PhD
Phone
144127932
Ext
+33
Email
alemonnier@ghpsj.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Helene BEAUSSIER, PharmD, PhD
Phone
144127883
Ext
+33
Email
crc@ghpsj.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alban LE MONNIER, MD, PhD
Organizational Affiliation
Fondation Hôpital Saint-Joseph
Official's Role
Principal Investigator
Facility Information:
Facility Name
Groupe Hospitalier Paris Saint-Joseph
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alban LE MONNIER, MD, PhD
Phone
144127932
Ext
+33
Email
alemonnier@ghpsj.fr
Facility Name
Hôpital Sainte-Marie Paris
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernard Durand Gasselin, MD
Facility Name
Centre de SSR Pierre Chevalier
City
Toulon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Muriele PHILIP-DUTASTA, MD
Facility Name
Hôpital d'Instruction des Armées Sainte Anne,
City
Toulon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric Janvier, MD
Facility Name
Centre Hospitalier de Valenciennes
City
Valenciennes
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian CATTOEN, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
6886489
Citation
Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983 Jul;148(1):93-100. doi: 10.1093/infdis/148.1.93.
Results Reference
background
PubMed Identifier
22843784
Citation
Rousseau C, Poilane I, De Pontual L, Maherault AC, Le Monnier A, Collignon A. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis. 2012 Nov;55(9):1209-15. doi: 10.1093/cid/cis637. Epub 2012 Jul 25.
Results Reference
background
PubMed Identifier
10666429
Citation
Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
Results Reference
background
PubMed Identifier
11213096
Citation
Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.
Results Reference
background
PubMed Identifier
19941990
Citation
Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010 Jan 22;28(4):965-9. doi: 10.1016/j.vaccine.2009.10.144. Epub 2009 Nov 24.
Results Reference
background
PubMed Identifier
12595488
Citation
Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
Results Reference
background
PubMed Identifier
20089970
Citation
Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635.
Results Reference
background
PubMed Identifier
29538686
Citation
Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis. 2018 Aug 16;67(5):649-656. doi: 10.1093/cid/ciy171.
Results Reference
background
Learn more about this trial
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
We'll reach out to this number within 24 hrs